Combination drug regimens that incorporate anti-CD38 monoclonal antibodies, immunomodulatory drugs, proteasome inhibitors, and glucocorticoids are routinely used for the treatment of newly diagnosed multiple myeloma.1 Consequently, at the first relapse, patients have already been exposed to the most effective available drug classes and potentially have refractory disease, so…
The New England Journal of Medicine: Search Results in Hematology/Oncology
